• 2. November 2024

InDex Pharmaceuticals receives approval of the International Nonproprietary Name (INN) cobitolimod for their lead drug candidate Kappaproct®

ByInDex Pharmaceuticals

Feb 10, 2016

Teile den Beitrag mit Freunden